ProMIS Neurosciences Files 8-K

TL;DR

PMN filed an 8-K on Feb 25, 2025. Standard disclosure.

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on February 25, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is incorporated in Canada and headquartered in Toronto.

Why It Matters

This filing indicates routine corporate reporting and disclosure of financial information, which is essential for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for corporate disclosures and does not appear to contain significant new risks.

Key Numbers

• 001-41429 — SEC File Number (Identifies the company's filing with the SEC.)
• 98-0647155 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• AMORFIX LIFE SCIENCES LTD (company) — Former company name
• February 25, 2025 (date) — Date of report
• Toronto, Ontario (location) — Principal executive offices

FAQ

From the Filing

0001558370-25-001435.txt : 20250225 0001558370-25-001435.hdr.sgml : 20250225 20250225070123 ACCESSION NUMBER: 0001558370-25-001435 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250225 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProMIS Neurosciences Inc. CENTRAL INDEX KEY: 0001374339 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41429 FILM NUMBER: 25659333 BUSINESS ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 BUSINESS PHONE: 416-847-6898 MAIL ADDRESS: STREET 1: SUITE 200, 1920 YONGE STREET CITY: TORONTO STATE: A6 ZIP: M4S 3E2 FORMER COMPANY: FORMER CONFORMED NAME: AMORFIX LIFE SCIENCES LTD DATE OF NAME CHANGE: 20060831 8-K 1 pmn-20250225x8k.htm 8-K PROMIS NEUROSCIENCES INC._February 25, 2025 0001374339 false 0001374339 2025-02-25 2025-02-25 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 PROMIS NEUROSCIENCES INC. (Exact name of registrant as specified in its charter) ​ Canada      001-41429      98-0647155 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) ​ ​ Suite 200 , 1920 Yonge Street , Toronto , Ontario             M4S 3E2 (Address of principal executive offices)       (Zip Code) ​ Registrant’s telephone number, including area code: ( 416 ) 847-6898 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class      Trading Symbol(s)      Name of Each Exchange on Which Registered Common Shares, no par value per share ​ PMN The Nasdaq Capital Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company   ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ Item 7.01 Regulation FD Disclosure. On February 25, 2025, ProMIS Neurosciences Inc. (the “Company”) issued a press release (the “Press Release”) announcing important progress in the PRECISE-AD Phase 1b clinical trial with the dosing of multiple patients with its lead drug candidate, PMN310, designed for the treatment of Alzheimer’s disease. A copy of the press release is attached hereto as Exhib